CSPC Megalith Biopharmaceutical Co. Ltd. has discovered new antibody-drug conjugates (ADCs) consisting of antibodies targeting CUB domain-containing protein 1 (CDCP1) covalently linked to cytotoxic drugs potentially useful for the treatment of cancer.